Glaucoma News and Research

Latest Glaucoma News and Research

Probability of blindness from glaucoma drops by half, say researchers

A comparative long-range study by Mayo Clinic ophthalmology researchers shows that the probability of blindness from glaucoma 20 years after diagnosis has dropped by half in the last generation. The findings appear online in the "in press" section of the journal Ophthalmology.

22 Jan 2014

Study: Probability of blindness due to glaucoma has decreased by nearly half

The probability of blindness due to the serious eye disease glaucoma has decreased by nearly half since 1980, according to a study published this month in Ophthalmology, the journal of the American Academy of Ophthalmology. The researchers speculate that advances in diagnosis and therapy are likely causes for the decrease, but caution that a significant proportion of patients still progress to blindness.

21 Jan 2014

Sleeping position influences glaucoma visual loss

Researchers from South Korea suggest that patients with glaucoma should avoid sleeping on one side, after showing that it may be associated with greater visual field loss in the lower-positioned eye.

20 Jan 2014

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

ARIAD Pharmaceuticals, Inc. today announced the commercial availability of Iclusig (ponatinib) for adult patients with refractory chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia in the United States. ARIAD has begun shipping Iclusig to Biologics, Inc., its exclusive specialty pharmacy, which is now filling prescriptions from physicians and distributing the cancer medicine to patients.

18 Jan 2014

FDA approves Ocular Therapeutix’s ReSure Sealant for ophthalmic use

Ocular Therapeutix announced today it has received approval from the Food and Drug Administration to commercialize the ReSure Sealant in the United States, with an indication for prevention of postoperative fluid egress from incisions with a demonstrated wound leak following cataract surgery.

10 Jan 2014

Akorn acquires NDA and all rights to Betimol from Santen

Akorn, Inc., a niche generic pharmaceutical company, today announced that it has acquired the NDA and all rights to Betimol (timolol ophthalmic solution) 0.25% & 0.5% from Santen. Akorn plans to begin shipping Betimol in the first quarter of 2014.

9 Jan 2014

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma (melanoma that cannot be removed by surgery) or metastatic melanoma (melanoma which has spread to other parts of the body) with BRAF V600E or V600K mutations.

9 Jan 2014

Residual structures in brain play key role in restoring vision in stroke patients

Scientists know that vision restoration training (VRT) can help patients who have lost part of their vision due to glaucoma, optic nerve damage, or stroke regain some of their lost visual functions, but they do not understand what factors determine how much visual recovery is achieved.

6 Jan 2014

CF101 drug fails to meet primary efficacy endpoint in phase III study for Dry Eye Syndrome

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its subsidiary OphthaliX Inc. released results from a 24 week, placebo-controlled phase III study involving 237 patients with moderate-to-severe Dry Eye Syndrome who were treated with its licensed drug CF101, an A3 adenosine receptor agonist.

30 Dec 2013

Scientists develop new potential cure for rare eye disease

University of British Columbia and Vancouver Coastal Health scientists have developed a potential cure for a rare eye disease, showing for the first time that a drug can repair a birth defect.

22 Dec 2013

New optical device puts the power to detect retinal disease in the palm of a hand

A new optical device puts the power to detect eye disease in the palm of a hand. The tool-about the size of a hand-held video camera-scans a patient's entire retina in seconds and could aid primary care physicians in the early detection of a host of retinal diseases including diabetic retinopathy, glaucoma and macular degeneration.

22 Dec 2013

Spaceflights cause cellular-level damage and may lead to long-term vision problems

Those who travel to space are rewarded with a beautiful sight - planet Earth. But the effects of space travel on the human sense of sight aren't so beautiful. More than 30 percent of astronauts who returned from two-week space shuttle missions and 60 percent who spent six months aboard the International Space Station were diagnosed with eye problems. Two recent investigations examined mechanisms that may explain eye changes in spaceflight, help find ways to minimize this health risk to astronauts and eventually prevent and treat eye diseases on Earth.

13 Dec 2013

EyeTechCare's new EyeOP1 device now available in six more French health care facilities

EyeTechCare SA, which develops non-invasive therapeutic medical devices for the ophthalmology market based on the use of ultrasound, today announces that six more health care facilities in France now have the new EyeOP1 device.

11 Dec 2013

Researchers develop new drug-eluting contact lens for prolonged delivery of glaucoma medication

10 Dec 2013

Researchers one step closer to development of drug-eluting contact lens for glaucoma treatment

For nearly half a century, contact lenses have been proposed as a means of ocular drug delivery that may someday replace eye drops, but achieving controlled drug release has been a significant challenge. Researchers at Massachusetts Eye and Ear/Harvard Medical School Department of Ophthalmology, Boston Children's Hospital, and the Massachusetts Institute of Technology are one step closer to an eye drop-free reality with the development of a drug-eluting contact lens designed for prolonged delivery of latanoprost, a common drug used for the treatment of glaucoma, the leading cause of irreversible blindness worldwide.

9 Dec 2013

Director of Scheie Eye Institute honored with WIO's Suzanne Veronneau Troutman Award

Joan M. O'Brien, MD, the George E. de Schweinitz and William F. Norris Professor of Ophthalmology, chair of the Department of Ophthalmology and director of the Scheie Eye Institute at the Perelman School of Medicine at the University of Pennsylvania, was recently presented with the Women in Ophthalmology's Suzanne Veronneau Troutman Award.

26 Nov 2013

Genetic diagnostic test for inherited eye diseases now available from Mass. Eye and Ear

The Massachusetts Eye and Ear/Harvard Medical School Department of Ophthalmology today announced the availability of a comprehensive genetic diagnostic test for inherited eye diseases.

22 Nov 2013

Research shows oral contraceptive use over three years could be a risk factor for glaucoma

Research presented today, at the 117th Annual Meeting of the American Academy of Ophthalmology in New Orleans, has found that women who have taken oral contraceptives for three or more years are twice as likely to suffer from glaucoma, one of the leading causes of blindness which affects nearly 60 million worldwide. The researchers caution gynecologists and ophthalmologists to be aware of the fact that oral contraceptives might play a role in glaucomatous diseases, and inform patients to have their eyes screened for glaucoma if they also have other risk factors.

19 Nov 2013

ACADIA Pharmaceuticals initiates pimavanserin Phase II trial in ADP patients

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it has initiated a Phase II feasibility trial designed to examine the efficacy and safety of pimavanserin as a treatment for patients with Alzheimer's disease psychosis.

15 Nov 2013

Researchers study link between vision loss and Alzheimer's disease

An international team of researchers studying the link between vision loss and Alzheimer's disease report that the loss of a particular layer of retinal cells not previously investigated may reveal the disease's presence and provide a new way to track disease progression.

14 Nov 2013

Glaucoma News and Research

Latest Glaucoma News and Research

Probability of blindness from glaucoma drops by half, say researchers

Study: Probability of blindness due to glaucoma has decreased by nearly half

Sleeping position influences glaucoma visual loss

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

FDA approves Ocular Therapeutix’s ReSure Sealant for ophthalmic use

Akorn acquires NDA and all rights to Betimol from Santen

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

Residual structures in brain play key role in restoring vision in stroke patients

CF101 drug fails to meet primary efficacy endpoint in phase III study for Dry Eye Syndrome

Scientists develop new potential cure for rare eye disease

New optical device puts the power to detect retinal disease in the palm of a hand

Spaceflights cause cellular-level damage and may lead to long-term vision problems

EyeTechCare's new EyeOP1 device now available in six more French health care facilities

Researchers develop new drug-eluting contact lens for prolonged delivery of glaucoma medication

Researchers one step closer to development of drug-eluting contact lens for glaucoma treatment

Director of Scheie Eye Institute honored with WIO's Suzanne Veronneau Troutman Award

Genetic diagnostic test for inherited eye diseases now available from Mass. Eye and Ear

Research shows oral contraceptive use over three years could be a risk factor for glaucoma

ACADIA Pharmaceuticals initiates pimavanserin Phase II trial in ADP patients

Researchers study link between vision loss and Alzheimer's disease

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Glaucoma News and Research

Latest Glaucoma News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in